Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease (Q57396337)
article
Language:
Current Data About Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease
(P31) (Q13442814)

(P50) (Q56633150)
(P1932) John J.V. McMurray
(P1545) 8

(Q16561003)
(P1932) Giuseppe Remuzzi
(P1545) 12

(Q92434434)
(P1545) 7
(P1932) Janet B. McGill

(Q114398840)
(P1545) 10
(P1932) Hans-Henrik Parving

(Q91630122)
(P1545) 9
(P1932) Patrick S. Parfrey

(Q90134887)
(P1545) 6
(P1932) Andrew S. Levey

(Q114321706)
(P1545) 17
(P1932) Marc A. Pfeffer

(Q104110852)
(P1545) 16
(P1932) Robert D. Toto

(P304) 408-413

(P407) (Q1860)

(P433) 3

(P478) 149

(P577) +2005-03-00T00:00:00Z

(P921) (Q11068)
(P887)

(Q736715)
(P887)

(P1433) (Q2227156)

(P1476) "Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease" (language: en)

(P2093) T.-Christian H. Mix
(P1545) 1

Robert M. Brenner
(P1545) 2

Mark E. Cooper
(P1545) 3

Dick de Zeeuw
(P1545) 4

Peter Ivanovich
(P1545) 5

Brian J.G. Pereira
(P1545) 11

Ajay K. Singh
(P1545) 13

Scott D. Solomon
(P1545) 14

Catherine Stehman-Breen
(P1545) 15

other details
description article

External Links
(P356) 10.1016/J.AHJ.2004.09.047
(P698) 15864229